Countries
Institutions
Fields
Rankings
Compare

Search institutions, scholars, countries and publications

Sankore

Named after the University of Sankore in Timbuktu — one of the world’s oldest centres of learning. Every figure here is computed from work-level records in our own graph, never copied from a source’s summary count.

Built from

OpenAlex — works, authorships, subject classification
ROR — institutional identity
ORCID — researcher identity
Crossref — publisher confirmation

Browse

Countries
Institutions
Fields
Rankings
What we cover

Coverage is partial and says so. A country appears with its research output only once its works have been swept; until then the portal shows whatever the graph happens to hold for it and labels it as exactly that.

Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial

2025The Lancet HaematologyJournal

10.1016/s2352-3026(24)00384-3 Full text27 citations

Authors

14 authors across 14 institutions in 10 countries.

Miguel R AbboudFirst authorCorresponding
Rodolfo D Cançado
Mariane de Montalembert
as printed: Mariane De Montalembert
Wally R Smith
Hala Rimawi
Ersi Voskaridou
Birol Güvenç
Kenneth I Ataga
Deborah Keefe
Kai Grosch
Jimmy Watson
Evgeniya Reshetnyak
Michele L Nassin
Yvonne Dei‐AdomakohSenior author
- University of Ghana (GH)
- Korle Bu Teaching Hospital (GH)
as printed: Yvonne Dei-Adomakoh

Fields

Assignment is probabilistic — a work belongs to several fields in proportions.

Hemoglobinopathies and Related Disorderslevel 3 · 1.00
Blood groups and transfusionlevel 3 · 0.00
Myeloproliferative Neoplasms: Diagnosis and Treatmentlevel 3 · 0.00

Sources

Several sources describing one work is the point — it means the record rests on more than one authority.

openalexseen September 5, 2026
2025 · The Lancet Haematology · 27 citations
https://openalex.org/W4408348139

Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial · Sankore